Compare · AMGN vs TARS
AMGN vs TARS
Side-by-side comparison of Amgen Inc. (AMGN) and Tarsus Pharmaceuticals Inc. (TARS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and TARS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $239.09B, about 76.3x TARS ($3.14B).
- AMGN has been more active in the news (18 items in the past 4 weeks vs 12 for TARS).
- AMGN has more recent analyst coverage (25 ratings vs 13 for TARS).
- Company
- Amgen Inc.
- Tarsus Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $239.09B
- $3.14B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2020
- News (4w)
- 18
- 12
- Recent ratings
- 25
- 13
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Latest AMGN
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
- Director Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)
- Director Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)
- SVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)
- SVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)
- Truist reiterated coverage on Amgen with a new price target
- Oppenheimer reiterated coverage on Amgen with a new price target
- Morgan Stanley reiterated coverage on Amgen with a new price target
Latest TARS
- SEC Form 144 filed by Tarsus Pharmaceuticals Inc.
- Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease
- SEC Form 144 filed by Tarsus Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.
- SEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.
- Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events
- Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
- Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing